Phase 2 N=78 All-trans Retinoic Acid, and Arsenic +/- Idarubicin
Acute Promyelocytic Leukemia
Primary: Complete Response (CR) Rate — 55; 5; 15 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=78 S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Leukemia
Primary: Continuous Complete Remission at 3 Years — 74 percentage of participants
Phase 2 N=17 Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Acute Promyelocytic Leukemia
Primary: To Determine the Rate of Molecular Remission
Phase 3 N=105 S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
Leukemia
Primary: 3-year Disease-free Survival (DFS) Rate — 96; 100 percentage of patients
Phase 1 N=24 AC220 for Children With Relapsed/Refractory ALL or AML
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Phase 3 N=108 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Childhood Acute Promyelocytic Leukemia With PML-RARA · Myeloid Neoplasm
Primary: Event-free Survival (EFS) — 95.4; 82.9 Percentage of participants
Phase 3 N=301 Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Acute Myeloid Leukemia
Primary: Percentage of Patients With Adverse Events (AEs), Grade 3 & 4 AEs, Serious Adverse Events (SAEs), AEs Leading to Discontinuation, and Deaths up to 24 Months (M24)…
Phase 2 N=84 Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Complete Response — 0; 0 participants
Phase 1 N=16 KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory
Primary: Maximum Tolerated Dose (MTD) — 5; 5; 2 participants
Phase 2 N=1 Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement
Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL · Leukemia Cutis · Recurrent Acute Myeloid Leukemia
Primary: Incidence of Dose-limiting Toxicities (DLTs) (Phase Ib)
Phase 2 N=41 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Phase 2 N=48 Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities
Leukemia, Myeloid, Acute
Primary: Complete Remission Rate (CRm + CRi + CRc) — 0; 3; 0; 4 participants
Phase 3 N=754 Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Acute Myeloid Leukemia · Untreated Adult Acute Myeloid Leukemia
Primary: Event-free Survival (EFS) — 0.36; 0.41; 0.37 Proportion of participants — p=0.84
Phase 3 N=76 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Myelodysplastic Syndrome/Acute Myeloid Leukemia
Primary: Overall Survival (OS) (Phase II) — 6.2; 5.2; 7.4 months
Phase 2 N=46 Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Phase 2 N=52 LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)
Phase 2 N=57 A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Phase 2 N=5 A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
Acute Myeloid Leukemia
Primary: Percentage of Safety Events (Part 1, Japan Only) — 5; 0 Participants
Phase 2 N=14 Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Leukemia
Primary: Dose-limiting Toxicity — 0; 0 participants
N/A N=14 Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
Phase 2 N=255 A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Acute Myeloid Leukemia
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1B — 0; 0; 0; 0 Participants
Phase 2 N=10 Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants
Phase 2 N=172 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Complete Response Rate — 76; 24 participants
Phase 2 N=17 MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
Acute Myelogenous Leukemia
Primary: < 5% Marrow Blast, no Circulating Peripheral Blasts and Neutrophil Count of > 1 x 10^9/L — 5 Participants
Phase 2 N=16 Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
Leukemia
Primary: Participants With a Response CR + PR + CRi — 4; 1; 4 Participants
Phase 2 N=44 Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Number of Participants by Best Clinical Response Experienced — 20; 6; 6; 7 Participants
Phase 2 N=12 PXD101 in Treating Patients With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Complete Response Rate — 0 percentage of subjects
Phase 2 N=11 Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
Leukemia, Myelomonocytic, Acute
Primary: Overall Response Rate (Defined as Partial Remission or Better) to 3 Months of Treatment With Erlotinib — 0 percentage of participants
Phase 2 N=31 PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Adult Acute Myeloid Leukemia in Remission · Recurrent Adult Acute Myeloid Leukemia
Primary: Relapse-free Survival in Days — 142 days